用单克隆抗体栓塞静脉给药装置可降低成本并缩短椅上时间: 一项随机对照试验。

IF 1.3 4区 医学 Q3 NURSING
Francesca Boyte, Brighid Scanlon, Robyn Matthews, Elise Button, Lee Jones, Therese Hayes, Grant Partridge, Michael Smith, Glen Andrew Kennedy, Melissa Eastgate, Nicole Clare Gavin
{"title":"用单克隆抗体栓塞静脉给药装置可降低成本并缩短椅上时间: 一项随机对照试验。","authors":"Francesca Boyte, Brighid Scanlon, Robyn Matthews, Elise Button, Lee Jones, Therese Hayes, Grant Partridge, Michael Smith, Glen Andrew Kennedy, Melissa Eastgate, Nicole Clare Gavin","doi":"10.1188/24.CJON.E9-E15","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of efficiency measures.</p><p><strong>Objectives: </strong>The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions.</p><p><strong>Methods: </strong>A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab.</p><p><strong>Findings: </strong>There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"E9-E15"},"PeriodicalIF":1.3000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial.\",\"authors\":\"Francesca Boyte, Brighid Scanlon, Robyn Matthews, Elise Button, Lee Jones, Therese Hayes, Grant Partridge, Michael Smith, Glen Andrew Kennedy, Melissa Eastgate, Nicole Clare Gavin\",\"doi\":\"10.1188/24.CJON.E9-E15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of efficiency measures.</p><p><strong>Objectives: </strong>The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions.</p><p><strong>Methods: </strong>A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab.</p><p><strong>Findings: </strong>There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.</p>\",\"PeriodicalId\":10350,\"journal\":{\"name\":\"Clinical journal of oncology nursing\",\"volume\":\"28 5\",\"pages\":\"E9-E15\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical journal of oncology nursing\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1188/24.CJON.E9-E15\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NURSING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical journal of oncology nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1188/24.CJON.E9-E15","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0

摘要

背景:单克隆抗体是广泛使用的抗癌疗法。对非卧床护理的需求不断增加,因此有必要探索提高效率的措施:主要目的是评估用单克隆抗体处方药栓剂静脉注射给药装置对治疗椅时间和相关成本的影响。次要目标是评估超敏反应的相关发生率:澳大利亚布里斯班的一家大型三甲医院采用双臂设计进行了一项随机对照试验(N = 128)。纳入的单克隆抗体包括达拉单抗、奥比妥珠单抗、pembrolizumab和nivolumab:与对照组相比,奥比妥珠单抗、pembrolizumab 和 nivolumab 的治疗椅时间明显缩短。研究结果表明,对于某些单克隆抗体药物来说,这种引导干预措施可减少治疗椅时间和成本。未来的研究可以评估这种做法在其他肿瘤疗法中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial.

Background: Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of efficiency measures.

Objectives: The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions.

Methods: A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab.

Findings: There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
9.10%
发文量
127
审稿时长
6-12 weeks
期刊介绍: The Clinical Journal of Oncology Nursing (CJON) is an official publication of the Oncology Nursing Society (ONS) and is directed to the practicing nurse specializing in the care of patients with an actual or potential diagnosis of cancer. CJON is a vehicle to promote the mission of ONS, which is to advance excellence in oncology nursing and quality cancer care. The CJON mission is twofold: to provide practical information necessary to care for patients and their families across the cancer continuum and to develop publication skills in oncology nurses.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信